Dystrophic Epidermolysis Bullosa Management Market: Insights, historical data and Statistics 2023 to 2033Posted by Ganesh Shinde on February 17th, 2023  According to Future Market Insights, global Dystrophic Epidermolysis Bullosa Management is expected to grow at a CAGR of 5.7% between 2023 and 2033, reaching US$ 787.8 Million in 2033. With a rise in the prevalence of dystrophic epidermolysis bullosa, coupled with increased research for treating this condition, global dystrophic epidermolysis bullosa treatment is expected to grow substantially over the forecast period. A wound care regimen that incorporates contemporary wound care techniques along with the elimination of factors that can irritate and inflame the skin can detect and treat dystrophic epidermolysis bullosa. Increasing dermatologists advocate conforming to strict personal hygiene habits and moisturizing thoroughly after treatments for dystrophic epidermolysis bullosa. With regular skin care and hygiene, blisters without further damage or infection are expected to heal completely. In terms of convenience and effectiveness, aqueous disinfectants are excellent in treating DEB. Additionally, micro-adhesive silicone-based wound care is highly effective for people with dystrophic epidermolysis bullosa, particularly those with tough skin areas such as their elbows, shoulders, and trunks. In the future, topical antibiotic ointments will take over as the first line of treatment to cure wounds and prevent the spread of infection. Researchers are currently studying different approaches to treat EB, including the use of gene-corrected iPS cells from the patient's own body, gene editing technologies, and polymer-mediated DNA delivery methods, which have been successfully employed to treat EB. Several genetic diseases have been successfully treated with protein replacement therapies, and EB might be one of them. At the preclinical level, a protein therapy approach involving intravenous and intradermal injections of recombinant collagen VII appeared promising in treating DEB, but it will require further testing and development before it can be proven useful for treating patients. Competitive Landscape  Castle Creek Biosciences, Amryth Pharma, Krystal Biotech, Abeona Therapeutics, BridgeBio, Phoenix Tissue Repair, Wings Therapeutics, InMed Pharmaceuticals, Inc., Regenerx Biopharmaceuticals Inc., Holostem Terapie Avanzate S.r.l. Browse More Details@ https://www.futuremarketinsights.com/reports/dystrophic-epidermolysis-bullosa-management-market Key Segments Profiled in the Dystrophic Epidermolysis Bullosa Management Industry Survey By Disease Type:
By Drug Class:
By Distribution Channel:
Like it? Share it! More by this author |